Key terms

About DNLI

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest DNLI news

Apr 08 7:34pm ET Denali Therapeutics price target lowered to $32 from $70 at UBS by TipRanks Mar 22 4:03pm ET Denali Therapeutics files to sell 29.29M shares of common stock for holders by TipRanks Mar 05 4:06am ET Analysts Offer Insights on Healthcare Companies: Straumann Holding AG (Six Swiss: CH:STMN), Denali Therapeutics (DNLI) and arGEN X (GB:0QW0) by TipRanks Mar 01 11:04am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Mar 01 7:47am ET Denali Therapeutics (DNLI) Gets a Buy from Oppenheimer by TipRanks Mar 01 1:00am ET Strong Growth and Value Potential Justify Buy Rating for Denali Therapeutics Despite Dilution by TipRanks Feb 28 7:45am ET Buy Rating Affirmed for Denali Therapeutics Amid Promising Pipeline and Strategic FDA Engagement by TipRanks Feb 28 7:35am ET Buy Rating Affirmed on Denali Therapeutics Amid Promising DNL310 Progress and ETV Technology Potential by TipRanks Feb 28 7:31am ET Denali Therapeutics price target lowered to $95 from $105 at H.C. Wainwright by TipRanks Feb 28 7:06am ET Buy Rating Affirmed for Denali Therapeutics on Strong Pipeline and Extended Cash Runway by TipRanks Feb 28 6:59am ET Strong Buy Rating for Denali Therapeutics: Financial Stability and Promising Clinical Advancements by TipRanks Feb 28 6:28am ET Denali Therapeutics: Strong Buy Rating Backed by Financial Fortitude and Strategic Pipeline Advancements by TipRanks Feb 27 1:00pm ET Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Denali Therapeutics (DNLI) by TipRanks Feb 27 8:31am ET Denali Therapeutics to sell 3.24M shares at $17.07 in private placement by TipRanks Feb 27 8:12am ET Denali Therapeutics Strengthens R&D with $500M Investment by TipRanks Feb 27 8:08am ET Denali Therapeutics expects cash runway to extend into 2028 by TipRanks Feb 27 8:07am ET Denali Therapeutics reports Q4 EPS (86c), consensus (80c) by TipRanks Feb 22 7:04am ET Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Treace Medical Concepts (TMCI) by TipRanks Feb 22 6:15am ET Buy Rating on Denali Therapeutics: Anticipating Accelerated FDA Approval with CSF HS Biomarker Breakthrough by TipRanks Feb 22 1:35am ET Buy Rating Affirmed for Denali Therapeutics Amid Favorable Biomarker-Based Approval Prospects by TipRanks Feb 20 6:36pm ET Denali Therapeutics’ treatment of MPS IIIA granted FDA orphan designation by TipRanks Feb 20 8:59am ET Denali Therapeutics ALS study failue ‘clearing event,’ says B. Riley by TipRanks Feb 20 8:55am ET Denali continues decline after Sanofi ALS study failure by TipRanks Feb 19 5:30am ET Analysts’ Top Healthcare Picks: IQVIA Holdings (IQV), Denali Therapeutics (DNLI) by TipRanks Feb 16 5:45pm ET Maintaining Buy on Denali Therapeutics: A Resilient Pipeline Despite Setbacks Offers Favorable Risk-Reward by TipRanks Feb 16 5:31pm ET Denali Therapeutics price target lowered to $27 from $32 at Citi by TipRanks Feb 16 2:25pm ET Maintaining Buy Rating: Denali Therapeutics’ Long-Term Growth Outlook Despite HIMALAYA Study Setback by TipRanks Feb 16 8:14am ET Denali Therapeutics’ ALS Drug Fails Phase 2, Yet MS Trial Continues by TipRanks Feb 09 8:01am ET Analysts Are Bullish on Top Healthcare Stocks: Denali Therapeutics (DNLI), Illumina (ILMN) by TipRanks Feb 08 6:20am ET Analysts Conflicted on These Healthcare Names: Denali Therapeutics (DNLI), BridgeBio Pharma (BBIO) and 23andMe Holding (ME) by TipRanks Feb 07 9:55pm ET Buy Rating for Denali Therapeutics Backed by Promising DNL310 Clinical Data and Accelerated Approval Potential by TipRanks

No recent press releases are available for DNLI

DNLI Financials

1-year income & revenue

Key terms

DNLI Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

DNLI Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming